Astellas Homepage | Astellas Innovation Management LLC

News

News / General News

Mar 18, 2019

Astellas Launches PROGRAF^® Granules (tacrolimus for oral suspension) in the U.S. for Pediatric Liver, Heart, and Kidney Transplant Patients

News / General News

Feb 20, 2019

Astellas and WiserCare Announce Collaboration to Improve Patient Experience - Joint Project Will Explore Enhancements to Patient Communication and Shared Decision-Making -

News / General News

Feb 11, 2019

Phase 3 ARCHES Trial Shows XTANDI^® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer

News / General News

Dec 20, 2018

Astellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI^® (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer

News / General News

Dec 14, 2018

Astellas Acquires Potenza Therapeutics - Acquisition adds clinical stage novel immuno-oncology programs to Astellas’ oncology pipeline -

News / General News

Nov 29, 2018

XOSPATA^® (gilteritinib) Approved by U.S. FDA for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation